Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Rhabdomyosarcoma, child
Stage/Subtype:  recurrent childhood rhabdomyosarcoma
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 44 for your search:
Start Over
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: SHEBA-06-4013-IK-CTIL, NCT00339118
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NICHD
Protocol IDs: PPRU 10762, NCT00491946
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Aerosol IL-2 for Pulmonary Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCI-2012-00788, NCT01590069
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: 1075/01 PEI, NCT01919866
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABI-007-PST-001, NCT01962103
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: 1000046233, IND.217, NCT02303028
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 months to 30 years
Sponsor: NCI
Protocol IDs: NCI-2014-01222, ADVL1412, UM1CA097452, NCT02304458
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 271296-HMO-CTIL, NCT00149006
Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: Other
Protocol IDs: NAVE-CYCLO, NCT00180947
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CRAD001CBR08T, NCT01216839
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 5 to 49
Sponsor: Other
Protocol IDs: NCCCTS-08-322, NCT01380275
CREATE: Cross-tumoral Phase 2 With Crizotinib
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: EORTC-90101, 2011-001988-52, NCT01524926
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 7943, NCI-2012-00052, IRB# 7943, NCT01532687
A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634
Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CR0113061, NCT01807468
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116731, NCT01956669
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: UC-0105/1303, 2013-000885-13, NCT02034981
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: STIR Trial, NCT02100891
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Phase: Phase II
Type: Treatment
Status: Active
Age: 14 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ONC2014-001, 1R44CA183075-01A1, NCT02423863
Start Over